Organization
Cross Cancer Institute
10 abstracts
Abstract
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial.Org: Princess Margaret Cancer Centre, University Health Network, Genome Sciences Centre, BCCA, The Ottawa Hospital Cancer Centre, Oregon Health & Science University,
Abstract
A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).Org: Juravinski Cancer Inst, BCCA, Sindi Ahluwalia Hawkins Centre for the Southern Interior, Princess Margaret - University Health Network, Juravinski Cancer Centre, McMaster University,
Abstract
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.Org: Centre hospitalier de l'Université de Montréal, Cross Cancer Institute, London Health Science Centre, Division of Medical Oncology, London Health Sciences Centre & Western University, Jewish General Hospital, Lady Davis Institute, McGill University,
Abstract
Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.Org: University Health Network, BCCA Vancouver Cancer Centre, The Ottawa Hospital Cancer Centre, Providence Cancer Institute, Queen's University, Belfast,
Abstract
BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.Org: Trinity St. James’s Cancer Institute, Cross Cancer Institute, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University Health System, Princess Margaret Cancer Centre,
Abstract
Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.Org: University of Calgary, Cross Cancer Institute, Tom Baker Cancer Center, Tom Baker Cancer Centre,
Abstract
A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.Org: Cross Cancer Institute, Centre Hospitalier de l’Université de Montréal/CRCHUM, Princess Margaret - University Health Network, BC Cancer Centre for Lymphoid Cancer, Pacylex Pharmaceuticals, Inc.,
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,